688382 Stock Overview
A clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
InventisBio Co., Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.29 |
| 52 Week High | CN¥15.49 |
| 52 Week Low | CN¥6.50 |
| Beta | 0.31 |
| 1 Month Change | 26.57% |
| 3 Month Change | 60.23% |
| 1 Year Change | -13.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.62% |
Recent News & Updates
Shareholder Returns
| 688382 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.2% | -0.7% | 0.4% |
| 1Y | -13.1% | -18.4% | 12.3% |
Return vs Industry: 688382 exceeded the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 688382 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 688382 volatility | |
|---|---|
| 688382 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688382's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688382's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 188 | Yaolin Wang | www.inventisbio.com |
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications.
InventisBio Co., Limited Fundamentals Summary
| 688382 fundamental statistics | |
|---|---|
| Market cap | CN¥7.09b |
| Earnings (TTM) | -CN¥348.02m |
| Revenue (TTM) | CN¥77.51m |
91.4x
P/S Ratio-20.4x
P/E RatioIs 688382 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688382 income statement (TTM) | |
|---|---|
| Revenue | CN¥77.51m |
| Cost of Revenue | CN¥7.03m |
| Gross Profit | CN¥70.48m |
| Other Expenses | CN¥418.50m |
| Earnings | -CN¥348.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 90.93% |
| Net Profit Margin | -448.98% |
| Debt/Equity Ratio | 0% |
How did 688382 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 04:33 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InventisBio Co., Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Xiaoyi Qu | China International Capital Corporation Limited |
| Tan Huan Gan | Citic Securities Co., Ltd. |